A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2011
12/15/2011	US20110305752 Liposome-encapsulated glutathione for oral administration
12/15/2011	US20110305751 Glutathione-based drug delivery system
12/15/2011	US20110305750 Membrane type-1 matrix metalloprotein inhibitors and uses thereof
12/15/2011	US20110305749 HIV-1 Envelope Polypeptides for HIV Vaccine
12/15/2011	US20110305748 Vaccines for Pandemic Influenza
12/15/2011	US20110305747 Combination of dapsone with other anti-acne agents
12/15/2011	US20110305746 Patch for treating constipation using crude drugs
12/15/2011	US20110305745 Pollulan regenerative matrix
12/15/2011	US20110305744 Preparation for vaginal and rectal use and relative production method
12/15/2011	US20110305743 Ocular implant made by a double extrusion process
12/15/2011	US20110305742 Pharmaceutical compositions
12/15/2011	US20110305741 Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis
12/15/2011	US20110305740 Granulated powder containing vegetable proteins and maltodextrins, process for producing same, and uses thereof
12/15/2011	US20110305739 Method for Preparing a Non-Ionic Surfactant Stable Personal Care Dispersion
12/15/2011	US20110305738 Oxygenating Oral Compositions
12/15/2011	US20110305736 Stratiform Perforated Biomatrices
12/15/2011	US20110305735 Skin antiaging treatment
12/15/2011	US20110305734 Nucleic acid nanoparticles and uses therefor
12/15/2011	US20110305733 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them
12/15/2011	US20110305732 Methods and uses for inhibiting platelet coagulation
12/15/2011	US20110305731 Pharmaceutical formulation between jasmonates and it derivatives and nanocarries or microcarries
12/15/2011	US20110305730 Mono-and disaccharide derivatives
12/15/2011	US20110305646 Fatty acid monoglyceride compositions
12/15/2011	US20110305645 Crystal form of glycopyrronium chloride
12/15/2011	US20110305643 High Oil-Content Emollient Aerosol Foam Compositions
12/15/2011	US20110305642 Micronutrient supplement
12/15/2011	DE102010030053A1 Injizierbare Darreichungsform von Flupirtin Injectable dosage form of flupirtine
12/15/2011	DE102010026883A1 Transdermal system useful e.g. for indication of breast cancer with progesterone-receptor positive status, comprises e.g. aromatase inhibitor, active substance puller protection layer, active substance reservoir
12/15/2011	DE102010013064A1 Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut Novel carrier system for the transport of drugs into the skin
12/15/2011	CA2807271A1 Nanoparticle film delivery systems
12/15/2011	CA2802184A1 Oral iron deficiency therapy
12/15/2011	CA2802180A1 Solid compositions
12/15/2011	CA2802162A1 Ophthalmic compositions for the administration of liposoluble acitve ingredients
12/15/2011	CA2802093A1 Combination therapy with lisdexamphetamine and extended release guanfacine
12/15/2011	CA2802047A1 Oral spray formulations and methods for administration of sildenafil
12/15/2011	CA2802041A1 High oil-content emollient aerosol foam compositions
12/15/2011	CA2802031A1 Peptide-carrying nanoparticles
12/15/2011	CA2802021A1 Solid dispersions containing kinase inhibitors
12/15/2011	CA2802005A1 Compositions comprising buprenorphine
12/15/2011	CA2801984A1 Novel process
12/15/2011	CA2801983A1 Novel process
12/15/2011	CA2801982A1 Process for the preparation of oil in water emulsions
12/15/2011	CA2801891A1 Combination therapy methods for treating proliferative diseases
12/15/2011	CA2801676A1 Compositions
12/15/2011	CA2800428A1 Treatment of type 2 diabetes
12/15/2011	CA2800426A1 Diversion-resistant microgranules and microtablets
12/15/2011	CA2800181A1 A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
12/14/2011	EP2395021A1 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
12/14/2011	EP2395012A2 Modified siRNA molecules and uses thereof
12/14/2011	EP2394666A2 Pharmaceutical compositions comprising tgf- beta 1 inhibitor peptides
12/14/2011	EP2394656A2 Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices
12/14/2011	EP2394654A1 Herbal composition having cox-2 and immune activities and preparation method thereof
12/14/2011	EP2394653A1 Topical pharmaceutical compositions comprising mometasone furoate
12/14/2011	EP2394648A1 Pharmaceutical composition for oral administration
12/14/2011	EP2394644A2 Trimetazidine Formulation With Different Release Profiles
12/14/2011	EP2394643A1 Sustained-release formulations of topiramate
12/14/2011	EP2394642A1 5-ALA ester formulations and use thereof
12/14/2011	EP2394641A1 Pharmaceutical formulations of lornoxicam
12/14/2011	EP2394640A1 Improved liposomal formulations of lipophilic compounds
12/14/2011	EP2394639A1 Hyperthermic technologies and therapeutic uses thereof
12/14/2011	EP2394638A1 New Pharmaceutical Combinations
12/14/2011	EP2394637A1 Process for obtaining sterile brinzolamide suspensions
12/14/2011	EP2394636A1 Method for treating retinal conditions using an intraocular tamponade
12/14/2011	EP2393978A1 Method for coating microspheres onto a flexible material
12/14/2011	EP2393881A1 Natural colorant and methods thereof
12/14/2011	EP2393837A1 Process for purifying guar
12/14/2011	EP2393517A1 Compositions and uses to govern cancer cell growth
12/14/2011	EP2393516A1 Stable, taste and odor masked pharmaceutical compositions comprising acetylcystein and vitamin c
12/14/2011	EP2393508A1 Glp-1 analogues pharmaceutical compositions
12/14/2011	EP2393501A1 Method and means for producing tissues and tissues obtained
12/14/2011	EP2393489A2 Moisture-activated granulation process
12/14/2011	EP2393487A1 Pharmaceutical compositions resistant to abuse
12/14/2011	EP2393486A1 Aceclofenac-containing controlled-release oral drug preparations and their manufacturing process
12/14/2011	EP2393485A2 Tablets for combination therapy
12/14/2011	EP2393484A1 Immediate release composition resistant to abuse by intake of alcohol
12/14/2011	EP2393483A1 Pharmaceutical compositions comprising brivaracetam
12/14/2011	EP2393482A2 Process for the preparation of a pharmaceutical composition comprising ezetimibe
12/14/2011	EP2393481A2 Nanofabricated membrane using polymerized proteoliposomes
12/14/2011	EP2393480A1 Methods of reducing the proliferation and viability of microbial agents
12/14/2011	EP2393479A2 Transdermal pharmaceutical preparations
12/14/2011	EP2393478A2 Taste and odor masked pharmaceutical compositions with high bioavailability
12/14/2011	EP2393477A1 Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
12/14/2011	EP2393476A2 Resveratrol compositions
12/14/2011	EP2393475A1 Orosoluble and/or effervescent compositions containing at least a salt of s- adenosyl methionine (same)
12/14/2011	EP2393474A2 Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
12/14/2011	EP2393473A1 Buccal application system comprising 17a-estradiol
12/14/2011	EP2393472A1 Amphiphile prodrugs
12/14/2011	EP2393355A1 Method of treating dry eye disease with azithromycin
12/14/2011	EP2272488B1 Vesicle and cosmetic containing the same
12/14/2011	EP2240198B1 Composition for absorption through mucous tissue
12/14/2011	EP2217219B1 A sublingual effervescent tablet of progesterone associated with cyclodextrin
12/14/2011	EP2217210B1 Sustained release tablets with hydromorphone
12/14/2011	EP2209501B1 Zibotentan composition containing mannitol and microcrystalline cellulose
12/14/2011	EP2104519B1 Film-forming gel composition for wound or skin care
12/14/2011	EP2018160B1 Modified release formulations containing drug-ion exchange resin complexes
12/14/2011	EP1908449B1 Sterilizer selective to cariogenic bacterium, and method for sterilization of cariogenic bacterium
12/14/2011	EP1809261B1 Non-gelatin soft capsule system
12/14/2011	EP1781593B1 Cationic lipids and methods of use
12/14/2011	EP1742638B1 Composition comprising a diuretic and cardiac glycoside for the treatment of dna viral infections of the eye
12/14/2011	EP1684792B1 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof

1 ... 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 ... 2991